Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

NCT01347866

Last updated date
Study Location
Ronald Reagan UCLA Medical Center
Los Angeles, California, 90095-6984, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Advanced Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histological or cytological diagnosis of advanced/metastatic solid tumor for which there is no currently clinically effective treatment.

- All tumor types for patients enrolled in Stage 1 of Arm C.

- For patients enrolled in Stage 2 of Arm C, advanced colorectal cancer (both KRAS mutated and KRAS wild type), which has progressed on irinotecan-based regimens, and pancreatic ductal adenocarcinoma after progression on first line treatment for metastatic/advanced disease.

- For patients enrolled in Stage 1 of Arm D, tumors with KRAS or BRAF mutation (archived or fresh biopsy). Patients with tumors harboring other mutations that activate the MAPK pathway may be enrolled upon agreement with the Sponsor.

- For patients enrolled in Stage 2 of Arm D, ovarian cancer which has progressed on prior platinum containing regimen or KRAS mutated non small cell lung cancer which has progressed on one prior regimen.

- Patients with colorectal cancer enrolled to both Arms must:

1. have received at least 6 weeks of irinotecan-based therapy (either as single agent or in combination with cytotoxic drugs or in combination with targeted therapies) as the last prior treatment

2. have progressed on or within 1 month of completing this irinotecan-based regimen

- All patients must provide an archived or fresh tumor sample.

- For a subset of patients fresh tumor biopsies are mandatory:

a. All patients with CRC enrolled to Stage 2 of Arm C must provide a fresh tumor biopsy at baseline. A subset of patients (10 or more) with at least 5 evaluable patients with CRC KRAS wild type must also provide tumor biopsy during treatment.

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) must be 0 or 1

- Adequate Bone Marrow, Renal, Cardiac, and Liver Function

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- -Patients with known active brain metastases


- -Chemotherapy, radiotherapy (other than palliative radiotherapy to lesions that will
not be followed for tumor assessment on this study, ie, non target lesions),
biological or investigational agents within 4 weeks of the start of the study
treatment (6 weeks for mitomycin C or nitrosoureas).


- -Any surgery (not including minor procedures such as lymph node biopsy, needle biopsy,
and/or placement of port-a-cath) within 4 weeks of start of the study treatment; or
not fully recovered from any side effects of previous procedures.


- -In Arm D only: Patients with glaucoma, intraocular pressure > 21 mmHg, history of
retinal vein occlusions, ocular ischemia or any other clinically significant
abnormality in the ophthalmologic exam which would make the patient inappropriate for
entry into this study


- -For patients enrolling in Stage 2 prior therapy with an agent that is known or
proposed to be active by action on PI3K and/or mTOR.


- -Prior high dose chemotherapy requiring hematopoietic stem cell transplantation within
12 months of study treatment start.


- -Known impaired pulmonary function or demonstrated to be impaired by Pulmonary
Function Test (PFT) for patients who present with clinical suggestion of impairment.


- -Uncontrolled or significant cardiovascular disease


- -Current use or anticipated need for food or drugs that are known potent CYP3A4
inhibitors


- - Current or anticipated need for food or drugs that are known potent CYP3A4 inducers

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Advanced CancerClinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer NCT01347866
  1. Los Angeles, California
  2. Los Angeles, California
  3. Los Angeles, California
  4. Los Angeles, California
  5. Santa Monica, California
  6. Santa Monica, California
  7. Aurora, Colorado
  8. Aurora, Colorado
  9. Aurora, Colorado
  10. Aurora, Colorado
  11. Charleston, South Carolina
  12. Charleston, South Carolina
  13. Charleston, South Carolina
  14. Mount Pleasant, South Carolina
  15. North Charleston, South Carolina
  16. Toronto, Ontario
  17. Milano,
  18. Barcelona,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced CancerA Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) NCT02554812
  1. Malvern, Victoria
  2. Encinitas, California
  3. La Jolla, California
  4. La Jolla, California
  5. La Jolla, California
  6. La Jolla, California
  7. La Jolla, California
  8. Los Angeles, California
  9. Los Angeles, California
  10. Los Angeles, California
  11. Los Angeles, California
  12. San Diego, California
  13. San Diego, California
  14. Vista, California
  15. Washington, District of Columbia
  16. Aventura, Florida
  17. Miami Beach, Florida
  18. Sarasota, Florida
  19. Tampa, Florida
  20. Iowa City, Iowa
  21. Ann Arbor, Michigan
  22. Ann Arbor, Michigan
  23. Detroit, Michigan
  24. Detroit, Michigan
  25. Farmington Hills, Michigan
  26. Northville, Michigan
  27. New York, New York
  28. New York, New York
  29. New York, New York
  30. New York, New York
  31. New York, New York
  32. New York, New York
  33. New York, New York
  34. New York, New York
  35. Clinton, North Carolina
  36. Goldsboro, North Carolina
  37. Jacksonville, North Carolina
  38. Wilson, North Carolina
  39. Philadelphia, Pennsylvania
  40. Providence, Rhode Island
  41. Providence, Rhode Island
  42. Sioux Falls, South Dakota
  43. Sioux Falls, South Dakota
  44. Sioux Falls, South Dakota
  45. Sioux Falls, South Dakota
  46. Nashville, Tennessee
  47. Nashville, Tennessee
  48. Nashville, Tennessee
  49. Nashville, Tennessee
  50. Dallas, Texas
  51. Dallas, Texas
  52. Houston, Texas
  53. Seattle, Washington
  54. Seattle, Washington
  55. Camperdown, New South Wales
  56. Camperdown, New South Wales
  57. Macquarie University, New South Wales
  58. Macquarie University, New South Wales
  59. North Sydney, New South Wales
  60. North Sydney, New South Wales
  61. Old Toongabie, New South Wales
  62. Brighton, Victoria
  63. Brighton, Victoria
  64. Heidelberg, Victoria
  65. Malvern, Victoria
  66. Malvern, Victoria
  67. Malvern, Victoria
  68. Malvern, Victoria
  69. New South Wales,
  70. New South Wales,
  71. Edmonton, Alberta
  72. Vancouver, British Columbia
  73. Ottawa, Ontario
  74. Toronto, Ontario
  75. Montreal, Quebec
  76. Montreal, Quebec
  77. Villejuif, Cedex
  78. Villejuif,
  79. Kashiwa, Chiba
  80. Chuo-ku, Tokyo
  81. Warszawa, Mazowieckie
  82. Poznan, Wielkopolskie
  83. Poznan, Wielkopolskie
  84. Poznan, Wielkopolskie
  85. Poznan, Wielkopolskie
  86. Taipei,
  87. Taipei,
  88. London,
  89. London,
  90. London,
  91. London,
  92. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced CancerHepatic Impairment Study For Crizotinib In Advanced Cancer Patients NCT01576406
  1. Los Angeles, California
  2. Los Angeles, California
  3. Los Angeles, California
  4. Los Angeles, California
  5. Aurora, Colorado
  6. Aurora, Colorado
  7. Aurora, Colorado
  8. Aurora, Colorado
  9. Atlanta, Georgia
  10. Atlanta, Georgia
  11. Atlanta, Georgia
  12. Atlanta, Georgia
  13. Atlanta, Georgia
  14. Columbus, Ohio
  15. Columbus, Ohio
  16. Columbus, Ohio
  17. Columbus, Ohio
  18. Columbus, Ohio
  19. San Antonio, Texas
  20. San Antonio, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
Official Title  ICMJE A Multi-arm Phase 1 Dose Escalation Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of The Dual Pi3k/Mtor Inhibitors Pf-04691502 And Pf-05212384 In Combination With Experimental Or Approved Anticancer Agents In Patients With Advanced Cancer
Brief Summary After the fourth protocol amendment two study arms are evaluated in this clinical protocol: PD-0325901 (oral MEK inhibitor) plus PF-05212384 (intravenous PI3K/mTOR inhibitor) and PF-05212384 plus irinotecan. The study will assess safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer. Once the maximum tolerated doses are identified, further assessment of these combinations will be done in patients with previously treated metastatic colorectal or pancreatic cancer for the PF-05212384 plus irinotecan arm and in patients with ovarian cancer or KRAS mutated non small cell lung cancer for the combination of PF-05212384 plus PD-0325901.
Detailed Description The study was prematurely discontinued as a result of an internal portfolio review on April 1, 2015. The decision to terminate was not due to any safety or efficacy data.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Masking: None (Open Label)
Primary Purpose: Basic Science
Condition  ICMJE Advanced Cancer
Intervention  ICMJE
  • Drug: PF-05212384
    PF-05212384 intravenous infusion weekly starting at 110 mg.
  • Drug: PD-0325901
    PD-0325901 Oral twice daily (BID) dosing 2 mg BID 3 weeks on 1 week off
  • Drug: PF-05212384
    PF-05212384 intravenous infusion weekly starting at 95 mg.
  • Drug: irinotecan
    Irinotecan by intravenous infusion at 180 mg/m2 every two weeks (Q x 2 week)
Study Arms  ICMJE
  • Experimental: Arm D: PF-05212384 + PD-0325901
    Interventions:
    • Drug: PF-05212384
    • Drug: PD-0325901
  • Experimental: Arm C: PF-05212384 + irinotecan
    Interventions:
    • Drug: PF-05212384
    • Drug: irinotecan
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: January 13, 2016)
105
Original Estimated Enrollment  ICMJE
 (submitted: May 3, 2011)
100
Actual Study Completion Date  ICMJE December 2015
Actual Primary Completion Date December 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histological or cytological diagnosis of advanced/metastatic solid tumor for which there is no currently clinically effective treatment.
  • All tumor types for patients enrolled in Stage 1 of Arm C.
  • For patients enrolled in Stage 2 of Arm C, advanced colorectal cancer (both KRAS mutated and KRAS wild type), which has progressed on irinotecan-based regimens, and pancreatic ductal adenocarcinoma after progression on first line treatment for metastatic/advanced disease.
  • For patients enrolled in Stage 1 of Arm D, tumors with KRAS or BRAF mutation (archived or fresh biopsy). Patients with tumors harboring other mutations that activate the MAPK pathway may be enrolled upon agreement with the Sponsor.
  • For patients enrolled in Stage 2 of Arm D, ovarian cancer which has progressed on prior platinum containing regimen or KRAS mutated non small cell lung cancer which has progressed on one prior regimen.
  • Patients with colorectal cancer enrolled to both Arms must:

    1. have received at least 6 weeks of irinotecan-based therapy (either as single agent or in combination with cytotoxic drugs or in combination with targeted therapies) as the last prior treatment
    2. have progressed on or within 1 month of completing this irinotecan-based regimen
  • All patients must provide an archived or fresh tumor sample.
  • For a subset of patients fresh tumor biopsies are mandatory:

    a. All patients with CRC enrolled to Stage 2 of Arm C must provide a fresh tumor biopsy at baseline. A subset of patients (10 or more) with at least 5 evaluable patients with CRC KRAS wild type must also provide tumor biopsy during treatment.

  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) must be 0 or 1
  • Adequate Bone Marrow, Renal, Cardiac, and Liver Function

Exclusion Criteria:

  • -Patients with known active brain metastases
  • -Chemotherapy, radiotherapy (other than palliative radiotherapy to lesions that will not be followed for tumor assessment on this study, ie, non target lesions), biological or investigational agents within 4 weeks of the start of the study treatment (6 weeks for mitomycin C or nitrosoureas).
  • -Any surgery (not including minor procedures such as lymph node biopsy, needle biopsy, and/or placement of port-a-cath) within 4 weeks of start of the study treatment; or not fully recovered from any side effects of previous procedures.
  • -In Arm D only: Patients with glaucoma, intraocular pressure > 21 mmHg, history of retinal vein occlusions, ocular ischemia or any other clinically significant abnormality in the ophthalmologic exam which would make the patient inappropriate for entry into this study
  • -For patients enrolling in Stage 2 prior therapy with an agent that is known or proposed to be active by action on PI3K and/or mTOR.
  • -Prior high dose chemotherapy requiring hematopoietic stem cell transplantation within 12 months of study treatment start.
  • -Known impaired pulmonary function or demonstrated to be impaired by Pulmonary Function Test (PFT) for patients who present with clinical suggestion of impairment.
  • -Uncontrolled or significant cardiovascular disease
  • -Current use or anticipated need for food or drugs that are known potent CYP3A4 inhibitors
  • - Current or anticipated need for food or drugs that are known potent CYP3A4 inducers
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   Italy,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01347866
Other Study ID Numbers  ICMJE B1271002
2011-001671-39 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date February 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP